Zachary D. Zuschlag

Zachary D. Zuschlag

Auto-generated profile, based on publicly available information

Zachary D. Zuschlag

Mental Health and Behavioral Sciences Service, James A. Haley Veterans' Hospital, Tampa, Florida

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

10 February 2021 in Psychiatry Research
Verified
Journal Article
Closed access
ZZZachary D. Zuschlag
Zachary D. Zuschlag
ECEbele Compean
Ebele Compean
PNPaul Nietert
Paul Nietert
SLSteven Lauzon
Steven Lauzon
MHMark Hamner
Mark Hamner
ZWZhewu Wang
Zhewu Wang

21 March 2022 in Depression and Anxiety
Verified
Journal Article
Closed access
ZWZhewu Wang
Zhewu Wang
ZZZachary D. Zuschlag
Zachary D. Zuschlag
UMUrsula S. Myers
Ursula S. Myers
MHMark Hamner
Mark Hamner

20 July 2021 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
ZZZachary D. Zuschlag
Zachary D. Zuschlag
This ASCP Corner article reviews and clarifies the effects of second-generation antipsychotics on suicide, including both suicidal ideations and behaviors.

2 March 2019 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
MHMark B. Hamner
Mark B. Hamner
MHMelba A. Hernandez-Tejada
Melba A. Hernandez-Tejada
ZZZachary D. Zuschlag
Zachary D. Zuschlag
DADeborah Agbor-Tabi
Deborah Agbor-Tabi
MHMichael Huber
Michael Huber
ZWZhewu Wang
Zhewu Wang
Posttraumatic stress disorder (PTSD) is often a chronic, disabling illness for which antidepressant medications (ie, SSRI) are considered the primary psychopharmacological treatment. However, many patients remain refractory to antidepressants alone or in combination with psychotherapy. Safe and effective treatments for individuals with refractory PTSD are needed. This study aimed to examine ziprasidone augmentation of SSRI treatment of PTSD. This was a 2-phase study. In phase 1, subjects were treated with paroxetine or sertraline for 8 weeks. Individuals refractory to the SSRI treatment then entered into phase II of the study and were randomized, in a double-blind fashion, to 8 weeks of treatment with either ziprasidone or placebo. The primary outcome measure was change in Clinician Administered PTSD Scale total scores with the intent-to-treat sample. Secondary outcome measures included Positive and Negative Syndrome Scale scores, measures of depression and anxiety, and safety measures. No significant differences were observed on the Clinician Administered PTSD Scale, Positive and Negative Syndrome Scale, or other outcome measures between ziprasidone and placebo groups. No significant differences were observed for safety measures including metabolic profiles, extrapyramidal symptoms/movement disorder rating scales, nor study dropout. Although no significant differences were noted in efficacy or safety measures between ziprasidone and placebo in this pilot study, the small sample size prevents definitive conclusions.

29 April 2021 in The Primary Care Companion For CNS Disorders
Verified
Journal Article
Closed access
PDF file
ZZZachary D. Zuschlag
Zachary D. Zuschlag
KLKatherine C. Leventhal
Katherine C. Leventhal
This report describes a case of misophonia-type hyperacusis that resolved after the administration of the SSRI sertraline.